# Graves Ophthalmopathy Market > Graves Ophthalmopathy Market Research Report By Treatment Type (Medical Therapy, Radiotherapy, Surgery), By Disease Severity (Mild, Moderate, Severe), By Patients' Population (Newly Diagnosed, Relapsed/Refractory, Resistant) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.56% - **2024:** $ 1.75 Billion - **2025:** $ 1.83 Billion - **2035:** $ 2.85 Billion - **Key Players:** Teva Pharmaceutical Industries Ltd (IL), Horizon Therapeutics plc (IE), AmgenInc (US), Bausch Health Companies Inc (CA), Santen Pharmaceutical Co Ltd (JP), Novartis AG (CH), AbbVie Inc (US), Regeneron Pharmaceuticals Inc (US) **Report ID:** MRFR/HC/38944-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/graves-ophthalmopathy-market-40990 --- ## Market Summary ## **Global Graves Ophthalmopathy Market Overview** As per MRFR analysis, the Graves Ophthalmopathy Market Size was estimated at 1.6 (USD Billion) in 2022.    The Graves Ophthalmopathy Market Industry is expected to grow from 1.67(USD Billion) in 2023 to 2.5 (USD Billion) by 2032. The Graves Ophthalmopathy Market CAGR (growth rate) is expected to be around 4.56% during the forecast period (2024 - 2032). ### **Key Graves Ophthalmopathy Market Trends Highlighted** The Graves Ophthalmopathy Market is supposed to get increasing sales owing to rising occurrence of Graves’ disease. Several key factors can be identified as active drivers of market growth, such as the deepening of patients’ knowledge about the disease, improvement of diagnostic methods, and better availability of specialized health services. In particular, novel concepts of immunotherapy and gene therapy offer new possibilities. Newest trends include increasing attention to the development of patient-centered, personalized medicines. In addition, there is an increase in telemedicine services for providing follow-up and care, especially in low-access areas. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Graves Ophthalmopathy Market Drivers** ### Increasing Prevalence of Thyroid Eye Disease The major driving factors of the growth of the Graves ophthalmopathy market comprise the increasing prevalence of thyroid eye disease. According to the American Thyroid Association, Graves’ disease affects around 1 in 200 individuals in the US. Furthermore, around 30% of individuals with this condition develop Graves ophthalmopathy. The rising incidence of thyroid eye disease is due to several factors, such as the advent of advanced diagnostic methods, growing knowledge about the condition, and changes in lifestyle.Overall, as the number of individuals with Graves ophthalmopathy continues to grow, there will also be an increase in the demand for viable solutions, which will drive the growth of this market. ### Technological Advancements in Treatment Options Technological advances with regards to treatment procedures to a significant extent, the Graves ophthalmopathy market is also being encouraged by technological advances with regards to treatment options. Indeed, over the past few years, several significant advances were made in the development of new, and more effective treatments for Graves ophthalmopathy. Both targeted therapies and biologics as well as surgical techniques made it possible to achieve significant improvements as far as this health-related issue is concerned.For instance, biologics, including teprotumumab, have already shown that they can reduce the severity of Graves ophthalmopathy and improve patient outcomes. It is expected that the Graves ophthalmopathy market will experience further growth due to the emergence of new treatment options as they continue to be developed. ### Growing Awareness and Patient Advocacy The awareness of Graves ophthalmopathy and the increasing advocacy for patients are also driving the growth of the Graves ophthalmopathy market. Patient advocacy groups and organizations have been instrumental in the awareness creation process and in their advocacy for better access to care. They have worked together to educate patients and interested parties on the condition. Furthermore, the advocacy groups have helped in ensuring that there is adequate access to care for patients.Otherwise, patients will demand care and support for the condition, eventually leading to the growth of the Graves ophthalmopathy market. ## **Graves Ophthalmopathy Market Segment Insights** ### **Graves Ophthalmopathy Market Treatment Type Insights** The Treatment Type segment of the Graves Ophthalmopathy Market is divided into Medical Therapy, Radiotherapy, and Surgery. Medical Therapy is the leading segment because medications, such as corticosteroids, immunosuppressive drugs, and biologics, used in curbing inflammation and suppressing the immune system are effective. Radiotherapy is another popular treatment. The treatment method utilizes radiation in reducing inflammation and shrinking the enlarged muscle. Finally, Surgery is a method of the last resort. Orbital decompression relieves pressure on the optic nerve by providing more space for the eye.The Graves Ophthalmopathy Market is worth USD 1.89 billion in 2024. It is estimated to expand at a CAGR of 4.8% from 2023 to 2032. The major drivers to this growth are the increasing prevalence of Graves’ disease, the ever-increasing health care expenditure and advancements in treatment. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Graves Ophthalmopathy Market Disease Severity Insights** The Graves Ophthalmopathy Market is segmented by disease severity into mild, moderate, and severe. The moderate segment is expected to hold the largest market share in 2023, accounting for around 45% of the Graves Ophthalmopathy Market revenue. The severe segment is expected to reach the highest CAGR of 5.2% during the forecast period. The mild segment is characterized by symptoms such as eyelid retraction, proptosis, and mild inflammation. The moderate segment includes patients with more severe symptoms, such as diplopia, corneal exposure, and optic nerve involvement.The severe segment includes patients with the most severe symptoms, such as blindness and disfigurement. The market growth for the moderate and severe segments is attributed to the increasing prevalence of Graves' disease, which is the underlying cause of Graves' ophthalmopathy. The rising awareness of the condition and the availability of new treatment options are also contributing to market growth. ### **Graves Ophthalmopathy Market Patients' Population Insights** The Graves Ophthalmopathy Market segmentation by Patients' Population into 'Newly Diagnosed', 'Relapsed/Refractory', and 'Resistant' provides valuable insights into the characteristics and dynamics of each patient group. In 2023, the 'Newly Diagnosed' segment accounted for a significant share of the Graves Ophthalmopathy Market revenue, driven by the increasing incidence of Graves' disease and the need for early diagnosis and treatment. This segment is expected to continue to grow steadily in the coming years due to the rising awareness of Graves' disease and the availability of advanced diagnostic techniques.The 'Relapsed/Refractory' segment represents patients who have experienced a relapse or have not responded to initial treatment. This segment is characterized by more severe symptoms and requires specialized treatment approaches. The increasing prevalence of relapsed/refractory Graves Ophthalmopathy is expected to drive the growth of this segment in the coming years. The 'Resistant' segment includes patients who do not respond to conventional treatment options and require aggressive therapies. This segment is relatively small but is expected to grow as the understanding of Graves Ophthalmopathy and its treatment modalities improves. ### **Graves Ophthalmopathy Market Regional Insights** The regional segmentation of the Graves Ophthalmopathy market offers insights into the market's geographic distribution and its performance across different regions. North America is expected to hold the largest market share in 2023, with a significant contribution from the United States. Europe is projected to follow North America, driven by the presence of a large patient population and well-established healthcare systems. The Asia Pacific region is anticipated to exhibit the highest growth rate during the forecast period, owing to rising awareness about the condition and increasing healthcare expenditure. South America and the Middle East and Africa are expected to account for a smaller share of the market but are projected to grow steadily over the forecast period. Key factors driving regional market growth include the prevalence of Graves' disease, healthcare infrastructure, government initiatives, and the availability of treatment options. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Graves Ophthalmopathy Market Key Players and Competitive Insights** Major players in Graves Ophthalmopathy Market are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolio, and forming strategic partnerships. Leading Graves Ophthalmopathy Market players are focusing on developing innovative treatments and therapies to cater to the evolving needs of patients. The Graves Ophthalmopathy Market industry is witnessing the emergence of novel therapeutic approaches, such as gene therapy and cell-based therapies, which hold promise for improving patient outcomes.  Furthermore, key players are actively involved in clinical trials and collaborations to evaluate the efficacy and safety of new treatment modalities. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotechnology firms, each bringing their unique strengths and expertise to the market.A leading player in the Graves Ophthalmopathy Market is Teva Pharmaceutical Industries Ltd. The company has a strong presence in the market with a broad portfolio of ophthalmic products, including treatments for Graves ophthalmopathy. Teva is committed to advancing research and development to bring innovative therapies to patients.  It has a robust pipeline of potential treatments for Graves ophthalmopathy, including novel formulations and targeted therapies. The company's global reach and established distribution channels provide it with a competitive advantage in the market.A notable competitor in the Graves Ophthalmopathy Market is Novartis AG. The company has a strong focus on ophthalmology and is dedicated to developing and commercializing innovative treatments for eye diseases. Novartis has a portfolio of products for Graves ophthalmopathy, including immunomodulatory therapies and surgical devices. The company's research and development efforts are centered on advancing the understanding of Graves ophthalmopathy and developing new treatments to improve patient outcomes. Novartis's global presence and strong brand reputation make it a formidable competitor in the market. ## **Key Companies in the Graves Ophthalmopathy Market Include** ## **Graves Ophthalmopathy Market Industry Developments** The Graves Ophthalmopathy Market is poised to reach a valuation of USD 2.5 billion by 2032, exhibiting a CAGR of 4.56% during the forecast period of 2024-2032. The increasing prevalence of Graves' disease, coupled with growing awareness of the condition, is driving market expansion. Recent advancements in treatment modalities, such as the introduction of targeted therapies and surgical techniques, are expected to further fuel market growth. Key players in the market are actively involved in research and development initiatives to enhance treatment outcomes and expand their product portfolios. Strategic collaborations and partnerships are also on the rise, aiming to combine expertise and resources to address unmet medical needs. ## **Graves Ophthalmopathy Market Segmentation Insights** ### **Graves Ophthalmopathy Market Treatment Type Outlook** ### **Graves Ophthalmopathy Market Disease Severity Outlook** ### **Graves Ophthalmopathy Market Patients' Population Outlook** ### **Graves Ophthalmopathy Market Regional Outlook** ## Market Drivers ### Rise of Personalized Medicine The Graves Ophthalmopathy Market is witnessing a shift towards personalized medicine, which tailors treatment strategies to individual patient profiles. This approach is particularly relevant in managing Graves Ophthalmopathy Market, where variations in disease presentation and response to treatment can be significant. The integration of genetic testing and biomarkers into clinical practice allows for more targeted therapies, potentially improving efficacy and reducing adverse effects. As healthcare systems increasingly adopt personalized medicine, the Graves Ophthalmopathy Market is likely to expand, driven by the demand for customized treatment plans that cater to the unique needs of patients. ### Increased Awareness and Diagnosis The Graves Ophthalmopathy Market is benefiting from increased awareness and improved diagnostic capabilities. Educational initiatives aimed at both healthcare professionals and the public have led to a greater understanding of the condition, resulting in earlier diagnosis and intervention. Enhanced diagnostic tools, such as optical coherence tomography and ultrasound, are facilitating more accurate assessments of disease severity. This heightened awareness is reflected in the rising number of diagnosed cases, which is projected to contribute to the growth of the Graves Ophthalmopathy Market. As more patients seek treatment, the demand for effective therapies is expected to rise. ### Growing Incidence of Thyroid Disorders The Graves Ophthalmopathy Market is influenced by the growing incidence of thyroid disorders, particularly hyperthyroidism. As the prevalence of conditions such as Graves' disease increases, so does the associated risk of developing Graves Ophthalmopathy Market. Epidemiological studies indicate that approximately 25-50% of individuals with Graves' disease may experience ocular manifestations. This rising incidence is likely to drive demand for effective treatment options within the Graves Ophthalmopathy Market. Healthcare providers are increasingly focusing on managing thyroid disorders, which in turn propels the need for specialized care in Graves Ophthalmopathy Market. ### Technological Advancements in Treatment The Graves Ophthalmopathy Market is experiencing a notable transformation due to technological advancements in treatment modalities. Innovations such as minimally invasive surgical techniques and advanced imaging technologies are enhancing the precision of diagnosis and treatment. For instance, the introduction of robotic-assisted surgeries has shown promise in improving surgical outcomes for patients with Graves Ophthalmopathy Market. Furthermore, the development of novel pharmacological agents, including monoclonal antibodies, is expanding the therapeutic options available. These advancements not only improve patient outcomes but also contribute to the overall growth of the Graves Ophthalmopathy Market, as they attract more healthcare providers to adopt these cutting-edge technologies. ### Advancements in Research and Development The Graves Ophthalmopathy Market is poised for growth due to ongoing advancements in research and development. Increased investment in clinical trials and studies aimed at understanding the pathophysiology of Graves Ophthalmopathy Market is leading to the discovery of novel therapeutic targets. Research initiatives are exploring the role of immune modulation and the potential for new drug formulations that could enhance treatment efficacy. As these developments progress, they are likely to result in innovative therapies entering the market, thereby expanding the Graves Ophthalmopathy Market and providing patients with more effective management options. ## Future Outlook The Graves Ophthalmopathy Market is projected to grow at a 4.56% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of targeted biologic therapies for enhanced efficacy. - Expansion of telemedicine platforms for remote patient monitoring. - Investment in AI-driven diagnostic tools for early detection. By 2035, the market is expected to exhibit robust growth, reflecting evolving treatment paradigms and increased patient access. ## Segment Insights ### By Treatment Type: Medical Therapy (Largest) vs. Surgery (Fastest-Growing) The treatment landscape for Graves Ophthalmopathy Market is primarily dominated by Medical Therapy, which holds the largest market share among the treatment types. This category includes therapeutic approaches such as corticosteroids, which are essential in managing inflammation and reducing symptoms. Surgery, while traditionally less prevalent, is gaining traction as it allows for direct and immediate structural changes in severe cases, catering to patients with persistent or worsening conditions. In recent years, the market has seen a significant shift with the rising adoption of surgical interventions, attributed to advancements in surgical techniques and increased awareness of the condition. Moreover, the growing emphasis on rapid recovery and effective aesthetic outcomes has positioned surgery as the fastest-growing treatment option, as practitioners and patients alike seek immediate and comprehensive solutions for Graves Ophthalmopathy Market. Medical Therapy: Dominant vs. Surgery: Emerging Medical Therapy for Graves Ophthalmopathy Market remains the cornerstone of treatment, offering a range of non-invasive options that effectively manage symptoms and provide significant relief to patients. This segment's dominance is attributed to its wide acceptance and established protocols in clinical practice. On the other hand, Surgery is emerging as a critical option, especially for patients with refractory symptoms who do not respond adequately to medical therapies. The rise of minimally invasive surgical techniques has enhanced its appeal, allowing surgeons to improve the patient's quality of life quickly. As awareness of the need for personalized treatment continues to grow, both segments are likely to adapt, potentially influencing future treatment preferences. ### By Disease Severity: Moderate (Largest) vs. Severe (Fastest-Growing) In the Graves Ophthalmopathy Market, disease severity segments reveal distinct patterns of market share distribution. The moderate severity category is the largest segment, given its significant prevalence among patients experiencing this autoimmune condition. Mild cases, while prevalent, account for a smaller part of the market compared to moderate and severe cases. Severe cases, though fewer in number, are gradually gaining attention due to the need for specialized interventions. Moderate (Dominant) vs. Severe (Emerging) The moderate severity segment stands out as the dominant force in the Graves Ophthalmopathy Market, characterized by a substantial patient base that necessitates management and treatment. These patients often experience bothersome symptoms, leading to increased healthcare utilization and treatment options. Conversely, the severe segment is emerging as a focal point for healthcare professionals, given the complexities associated with aggressive symptoms. This creates a growing demand for advanced therapies and interventions, positioning severe cases as a rapidly evolving area for market growth. This duality highlights a clear need for tailored approaches in treatment across the severity spectrum. ### By Patients' Population: Newly Diagnosed (Largest) vs. Relapsed/Refractory (Fastest-Growing) The Graves Ophthalmopathy Market exhibits notable distribution among the patients' population segments, primarily categorized into Newly Diagnosed, Relapsed/Refractory, and Resistant patients. The Newly Diagnosed segment constitutes the largest portion of the market share, representing a significant influx of patients entering the treatment landscape. Conversely, the Relapsed/Refractory segment is emerging as a key player, garnering an increasing share due to the complexities and challenges faced by patients whose conditions do not adequately respond to primary therapies. As the focus on Graves Ophthalmopathy Market intensifies, we observe significant growth trends driven by advancements in diagnostic methodologies and treatment options tailored for diverse patient needs. The Relapsed/Refractory segment is particularly noteworthy, as improved understanding of the disease and tailored therapies have led to better management strategies. The evolving treatment landscape and increased awareness are anticipated to drive demand in these segments, highlighting the importance of comprehensive care in managing Graves Ophthalmopathy Market. Newly Diagnosed (Dominant) vs. Relapsed/Refractory (Emerging) The Newly Diagnosed segment stands as the dominant force in the Graves Ophthalmopathy Market, characterized by a steady stream of patients who have recently received their diagnosis. This group significantly contributes to the overall market narrative, suggesting a need for robust support systems and early intervention strategies to address the timely management of symptoms. On the other hand, the Relapsed/Refractory segment is emerging as a growing concern, with patients facing challenges due to inadequate responses to standard treatments. This segment reflects the complexities of Graves Ophthalmopathy Market, demanding innovative approaches and personalized treatment plans to enhance patient outcomes. As healthcare systems adapt to address these diverse patient needs, both segments are becoming increasingly pivotal in shaping the future of care in this market. ## Regional Market Share Analysis The regional segmentation of the Graves Ophthalmopathy Market offers insights into the market's geographic distribution and its performance across different regions. North America is expected to hold the largest market share in 2023, with a significant contribution from the United States. Europe is projected to follow North America, driven by the presence of a large patient population and well-established healthcare systems. The Asia Pacific region is anticipated to exhibit the highest growth rate during the forecast period, owing to rising awareness about the condition and increasing healthcare expenditure. South America and the Middle East and Africa are expected to account for a smaller share of the market but are projected to grow steadily over the forecast period. Key factors driving regional market growth include the prevalence of Graves' disease, healthcare infrastructure, government initiatives, and the availability of treatment options. ## Competitive Benchmarking Major players in Graves Ophthalmopathy Market are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolio, and forming strategic partnerships. Leading Graves Ophthalmopathy Market players are focusing on developing innovative treatments and therapies to cater to the evolving needs of patients. The Graves Ophthalmopathy Market industry is witnessing the emergence of novel therapeutic approaches, such as gene therapy and cell-based therapies, which hold promise for improving patient outcomes.  Furthermore, key players are actively involved in clinical trials and collaborations to evaluate the efficacy and safety of new treatment modalities. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotechnology firms, each bringing their unique strengths and expertise to the market.A leading player in the Graves Ophthalmopathy Market is Teva Pharmaceutical Industries Ltd. The company has a strong presence in the market with a broad portfolio of ophthalmic products, including treatments for Graves ophthalmopathy. Teva is committed to advancing research and development to bring innovative therapies to patients.  It has a robust pipeline of potential treatments for Graves ophthalmopathy, including novel formulations and targeted therapies. The company's global reach and established distribution channels provide it with a competitive advantage in the market.A notable competitor in the Graves Ophthalmopathy Market is Novartis AG. The company has a strong focus on ophthalmology and is dedicated to developing and commercializing innovative treatments for eye diseases. Novartis has a portfolio of products for Graves ophthalmopathy, including immunomodulatory therapies and surgical devices. The company's research and development efforts are centered on advancing the understanding of Graves ophthalmopathy and developing new treatments to improve patient outcomes. Novartis's global presence and strong brand reputation make it a formidable competitor in the market. ## Recent News & Developments The Graves Ophthalmopathy Market is poised to reach a valuation of USD 2.5 billion by 2035, exhibiting a CAGR of 4.56% during the forecast period of 2024-2035. The increasing prevalence of Graves' disease, coupled with growing awareness of the condition, is driving market expansion. Recent advancements in treatment modalities, such as the introduction of targeted therapies and surgical techniques, are expected to further fuel market growth. Key players in the market are actively involved in research and development initiatives to enhance treatment outcomes and expand their product portfolios. Strategic collaborations and partnerships are also on the rise, aiming to combine expertise and resources to address unmet medical needs. ## Report Scope | MARKET SIZE 2024 | 1.746(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.826(USD Billion) | | MARKET SIZE 2035 | 2.852(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.56% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2023 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Teva Pharmaceutical Industries Ltd (IL), Horizon Therapeutics plc (IE), Amgen Inc (US), Bausch Health Companies Inc (CA), Santen Pharmaceutical Co Ltd (JP), Novartis AG (CH), AbbVie Inc (US), Regeneron Pharmaceuticals Inc (US) | | Segments Covered | Treatment Type, Disease Severity, Patients' Population, Regional | | Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the Graves Ophthalmopathy Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the Graves Ophthalmopathy market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Graves Ophthalmopathy Market?** A: The Graves Ophthalmopathy Market was valued at 1.746 USD Billion in 2024. **Q: What is the projected market size for Graves Ophthalmopathy by 2035?** A: The market is projected to reach 2.852 USD Billion by 2035. **Q: What is the expected CAGR for the Graves Ophthalmopathy Market from 2025 to 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 4.56%. **Q: Which treatment types are included in the Graves Ophthalmopathy Market segments?** A: The treatment types include Medical Therapy, Radiotherapy, and Surgery. **Q: What were the valuations for Medical Therapy in 2024 and its projected value in 2035?** A: Medical Therapy was valued at 0.873 USD Billion in 2024 and is projected to reach 1.392 USD Billion by 2035. **Q: How does the market for Severe disease severity compare to Mild and Moderate in 2024?** A: In 2024, Severe disease severity was valued at 0.35 USD Billion, while Mild and Moderate were valued at 0.698 USD Billion each. **Q: What is the projected market size for Newly Diagnosed patients by 2035?** A: The market for Newly Diagnosed patients is projected to reach 0.999 USD Billion by 2035. **Q: Which companies are considered key players in the Graves Ophthalmopathy Market?** A: Key players include Teva Pharmaceutical Industries Ltd, Horizon Therapeutics plc, and Amgen Inc, among others. **Q: What was the valuation for Radiotherapy in 2024 and its expected value in 2035?** A: Radiotherapy was valued at 0.523 USD Billion in 2024 and is expected to reach 0.845 USD Billion by 2035. **Q: What is the expected market performance for Relapsed/Refractory patients from 2025 to 2035?** A: The market for Relapsed/Refractory patients is projected to grow from 0.523 USD Billion in 2024 to 0.785 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/graves-ophthalmopathy-market-40990*